LoadingLoadingLoadingThe quick read
Latest quote
Net selling: insiders sold $15.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $2K to $30K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $15.9M and bought $0 of GILD stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. $15.9M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was O'Day, Daniel Patrick (Chairman & CEO), who sold $6.4M. The latest filing was on Oct 16, 2026.
Rep. Jared Moskowitz (D) bought $1K to $15K on May 6, 2026, disclosed 44 days later. Rep. Jared Moskowitz (D) bought $1K to $15K on May 6, 2026, disclosed 44 days later. In total, 1 member disclosed 2 GILD trades with trade dates in the last 180 days, filed a median 44 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (3)
Qube Research
$373.0M
added
D.E. Shaw
$261.9M
added
Squarepoint
$201.6M
added
No tracked top-trader positions in GILD right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Financial period
Q2 2026
Adjusted EPS
-$7.25 expected
Revenue
No comparable estimate
FY2026 guidance
$30.10B to $30.40B
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | -$6.75 / -$7.25Yahoo Finance | +6.86% beat | $7.80B / Unavailable | Unavailable |
| Mar 31, 2026 | May 7, 2026 | $2.03 / $1.91Yahoo Finance | +6.24% beat | $6.96B / Unavailable | Unavailable |
| Dec 31, 2025 | Feb 10, 2026 | $1.86 / $1.81Yahoo Finance | +2.82% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $2.47 / $2.14Yahoo Finance | +15.68% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | $2.01 / $1.95Alpha Vantage | +3.08% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 24, 2025 | $1.81 / $1.78Alpha Vantage | +1.69% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 11, 2025 | $1.90 / $1.70Alpha Vantage | +11.73% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | $2.02 / $1.55Alpha Vantage | +30.32% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 18, 2026
EPS expected
$1.90 to $2.68
Revenue expected
20 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $7.77B | $7.92B | $6.96B | $7.80B |
| Cost of what it sold | $1.57B | $1.62B | $1.45B | $1.58B |
| Gross profit | $6.20B | $6.30B | $5.51B | $6.22B |
| What it spent | ||||
| Research and development | $1.35B | $1.58B | $1.37B | $1.76B |
| Sales and admin | $528.0M | $652.0M | $553.0M | $1.92B |
| Other operating costs | $999.0M | $1.08B | $1.00B | $12.93B |
| Total operating expenses | $2.87B | $3.31B | $2.93B | $16.62B |
| What was left | ||||
| Operating profit | $3.33B | $2.99B | $2.69B | -$10.39B |
| Interest on debt | $256.0M | $255.0M | $240.0M | $247.0M |
| Profit before tax | $3.64B | $2.08B | $2.58B | -$10.25B |
| Tax | $589.0M | -$105.0M | $559.0M | $242.0M |
| Net profit | $3.05B | $2.18B | $2.02B | -$10.50B |
| EBITDA | $4.58B | $3.02B | $3.51B | -$9.31B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
What Amgen (AMGN)'s Tezspire Trial Win Means For Shareholders
NeutralOct 15Nektar Therapeutics (NKTR) Could Be 72% Undervalued On New Rezpegaldesleukin Data
NeutralOct 15Vir Biotechnology signs Gilead cancer deal with US$90M upfront
BullishOct 15Merck & Co. (NYSE:MRK): A Quality Investing Case With Strong ROIC but Revenue Growth Concerns
NeutralOct 15Why Nurix Therapeutics Stock Is In Focus After A Profit Swing
NeutralOct 15Gilead Sciences Stock Draws Wave Of Bullish Target Hikes
NeutralOct 14Gilead Sciences Inc Stock (GILD) Moved Up by 3.12% on Oct 14: Facts Behind the Movement
BullishOct 14Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
NeutralOct 14